Renaissance Technologies LLC Trims Holdings in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD)

Renaissance Technologies LLC decreased its holdings in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) by 59.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 59,491 shares of the company’s stock after selling 88,647 shares during the quarter. Renaissance Technologies LLC’s holdings in Cadrenal Therapeutics were worth $28,000 at the end of the most recent quarter.

Cadrenal Therapeutics Stock Up 7.4 %

Shares of Cadrenal Therapeutics stock opened at $14.50 on Tuesday. The firm has a market cap of $232.12 million, a price-to-earnings ratio of -46.77 and a beta of 1.81. Cadrenal Therapeutics, Inc. has a one year low of $5.40 and a one year high of $32.55.

Cadrenal Therapeutics (NASDAQ:CVKD) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($33.75) EPS for the quarter, topping analysts’ consensus estimates of ($285.60) by $251.85. On average, equities research analysts forecast that Cadrenal Therapeutics, Inc. will post -6.72 earnings per share for the current year.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.